Top Markets
Coin of the day
Definium Therapeutics, Inc. Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX
Rang in Aktien #3212
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Aktienkurs
$44.42
Zuletzt synchronisiert: 2026-08-25
Marktkapitalisierung
$5.90B
Veränderung (1 Tag)
2.66%
Veränderung (1 Jahr)
344.66%
Land
US
Handel Definium Therapeutics, Inc. (DFTX)

Kategorie

Kursverlauf für Definium Therapeutics, Inc. (DFTX)
Höchster Schlusskurs: $44.49 am 2026-08-01

Niedrigster Schlusskurs: $4.81 am 2016-11-01
Kursverlauf der Aktie von Definium Therapeutics, Inc. von 2016 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 65.08%
2025 74.98%
2024 107.98%
2023 34.70%
2022 -89.90%
2021 -40.72%
2020 7,946.66%
2019 -31.09%
2018 -81.58%
2017 -37.50%
2016 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$553.09 42.85%
US
$1.02K 44.02%
NL
$158.64 541.49%
US
$122.63 -12.26%
AU
$772.27 7.33%
CH